How much funding has Cleave Biosciences raised?

Cleave Biosciences has raised $89.0M in total funding, most recently a Series B round.

Who are Cleave Biosciences's investors?

Cleave Biosciences's investors include US Venture Partners, 5AM Ventures, Clarus Ventures, NEA, OrbiMed, Nextech Invest.

When was Cleave Biosciences founded?

Cleave Biosciences was founded in 2011.

Where is Cleave Biosciences headquartered?

Cleave Biosciences is headquartered in Burlingame, California, United States.

What industry is Cleave Biosciences in?

Cleave Biosciences operates in Biotech, Oncology.

How many employees does Cleave Biosciences have?

Cleave Biosciences has 11-50 employees.

Cleave Biosciences

Burlingame, United States · Founded 2011 · $89.0M raised

Biotech

Oncology

Headquarters: Burlingame, California
Employees: 11–50
Founded: 2011
Business Model: B2B

Website: cleavebio.com
Total Funding: $89.0M
Last Round: $37.0M Series BAug 2016
Rounds: 3

About

Cleave Biosciences (later renamed Cleave Therapeutics) is a biopharmaceutical company headquartered in Burlingame, California, focused on developing small molecule therapies targeting protein homeostasis and cellular stress pathways in cancer. The company's lead program centers on VCP/p97 inhibition as a novel mechanism for treating difficult-to-treat cancers.

Summary

Cleave Biosciences is a Biotech company based in Burlingame, United States, founded in 2011. It has raised $89.0M in total across 3 rounds, most recently a $37.0M Series B round in Aug 2016. Investors include US Venture Partners, 5AM Ventures and Clarus Ventures.

LinkedIn X (Twitter)